<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374540</url>
  </required_header>
  <id_info>
    <org_study_id>19859</org_study_id>
    <nct_id>NCT03374540</nct_id>
  </id_info>
  <brief_title>Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients</brief_title>
  <official_title>Comparative Effectiveness of Rivaroxaban and Warfarin for Stroke Prevention in Multi-morbid Patients With Nonvalvular Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this study is to evaluate the comparative safety and effectiveness of
      rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular
      atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday
      clinical practice.

      The primary objective in this study is to evaluate the combined end point of stroke or
      systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs.
      VKA.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
    <description>Without access to clinical information and event adjudication in administrative claims data, major bleeding will operationalized as hospital-related bleeding using a clinically validated algorithm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subtypes of major bleeding</measure>
    <time_frame>Retrospective analysis from January 1, 2011 to December 31, 2017</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">99999</enrollment>
  <condition>Nonvalvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin K antagonist(VKA)</arm_group_label>
    <description>Patients who initiated OAC treatment with VKA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY59-7939)</intervention_name>
    <description>15/20 mg</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K antagonist(VKA)</intervention_name>
    <description>Individually adjusted dose</description>
    <arm_group_label>Vitamin K antagonist(VKA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The source population of this study will be all the insured individuals included in the
        Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases (Truven
        MarketScan).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be oral anticoagulant naive during the 365 days before the day of the first qualifying
             oral anticoagulant (rivaroxaban or VKA) dispensing, and

          -  Have â‰¥365 days of continuous medical and prescription coverage before initiation of
             oral anticoagulation (which serves as the study's baseline period)

        Exclusion Criteria:

          -  &lt;18 years of age

          -  &lt;2 International Classification of Diseases, Ninth/Tenth Revision, Clinical
             Modification diagnosis codes for atrial fibrillation

          -  Valvular heart disease

          -  Transient cause of NVAF

          -  Venous thromboembolism

          -  Hip or knee arthroplasty

          -  Malignant cancer

          -  Pregnancy

          -  &gt;1 oral anticoagulant prescribed (on index date)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases</name>
      <address>
        <city>Multiple Locations</city>
        <state>Washington</state>
        <zip>20001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2017</study_first_submitted>
  <study_first_submitted_qc>December 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

